CoChat
Sign Up
Cited by 43Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major DepressionMaternal Mental Health During Pregnancy and Postpartum

The efficacy of reboxetine in the treatment‐refractory patients with panic disorder: an open label study

Dannon, P. N., Iancu, I., Grunhaus, L.·2002·Human Psychopharmacology: Clinical and Experimental
DOI 10.1002/hup.421
Open this paper in CoChat — free account

Abstract

Background and Objective: Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibitor (selective NRI), is effective in treating depression and may alleviate depression‐related anxiety. This study aimed to investigate the efficacy of reboxetine in the treatment of patients with panic disorder who did not respond to SSRIs. Method: In this 6‐week, open‐label study, 29 adult outpatients with panic disorder who had previously failed to respond to SSRI treatment received reboxetine 2 mg/day, titrated to a maximum of 8 mg/day over the first 10 days. Efficacy was assessed using the Panic Self‐Questionnaire (PSQ), the Hamilton Rating Scale for Anxiety (HAM‐A), the 17‐item Hamilton Rating Scale for Depression (HRSD) and the Global Assessment of Functioning (GAF) Scale. Results: The 24 patients who completed the study responded well to reboxetine treatment. Significant improvement (p < 0.001) was observed in the number of daily panic attacks, and on the scales measuring anxiety, depression and functioning. Reboxetine was generally well tolerated. Five patients withdrew due to adverse events. Conclusions: Reboxetine appears to be effective in the treatment of SSRI‐refractory panic disorder patients and warrants further clinical investigation. Copyright © 2002 John Wiley & Sons, Ltd.

Integrity signals

Registry

Crossref · 10.1002/hup.421

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is no unequivocal definition of treatment-resistant panic disorder, and very heterogeneous criteria have been used across studies, making interpretation of results uncertain.

    “Currently, there is no unequivocal definition of TRPD. Very heterogeneous criteria have been used across different studies, making interpretation of the results uncertain.”

    From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [17]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Dannon, P. N., Iancu, I., & Grunhaus, L.
Affiliations
Tel Aviv University (IL)
Corresponding author
Dannon, P. N.
ORCID
Venue
Human Psychopharmacology: Clinical and Experimental
Publisher
Wiley
Published
2002-07-22
Volume
17
Issue
7
Pages
329-333
ISSN
  • 0885-6222 (ISSN-L)
  • 1099-1077
DOI
10.1002/hup.421
OpenAlex
W2096281933
Cited by
41
References
32
Citations by year
2025: 1 · 2021: 1 · 2019: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 2 · 2012: 3
FWCI
5.73
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Human Psychopharmacology Clinical and Experimental (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
reboxetine, panic disorder, selective norepinephrine reuptake inhibitors, panic attacks, depression, adverse events, drug tolerability
MeSH terms
Reboxetine, Adult, Agoraphobia, Antidepressive Agents, Drug Resistance, Female, Humans, Male, Morpholines, Psychiatric Status Rating Scales, Panic Disorder, Selective Serotonin Reuptake Inhibitors, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review